CN109432388B - Composition of probiotics and glucosamine hydrochloride and application of composition in bone joint health - Google Patents
Composition of probiotics and glucosamine hydrochloride and application of composition in bone joint health Download PDFInfo
- Publication number
- CN109432388B CN109432388B CN201811594602.9A CN201811594602A CN109432388B CN 109432388 B CN109432388 B CN 109432388B CN 201811594602 A CN201811594602 A CN 201811594602A CN 109432388 B CN109432388 B CN 109432388B
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- calcium
- control group
- glucosamine hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 title claims abstract description 27
- 229960001911 glucosamine hydrochloride Drugs 0.000 title claims abstract description 27
- 239000006041 probiotic Substances 0.000 title claims abstract description 19
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 19
- 210000000988 bone and bone Anatomy 0.000 title abstract description 36
- 230000037231 joint health Effects 0.000 title abstract description 10
- 239000011575 calcium Substances 0.000 claims abstract description 88
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 87
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 86
- 230000037182 bone density Effects 0.000 claims abstract description 39
- 238000010521 absorption reaction Methods 0.000 claims abstract description 36
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 25
- 239000011707 mineral Substances 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 15
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 15
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 15
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 15
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 15
- 230000001737 promoting effect Effects 0.000 claims abstract description 15
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 14
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 14
- 239000005018 casein Substances 0.000 claims abstract description 14
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000021240 caseins Nutrition 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 235000013336 milk Nutrition 0.000 claims abstract description 14
- 239000008267 milk Substances 0.000 claims abstract description 14
- 210000004080 milk Anatomy 0.000 claims abstract description 14
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 8
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 4
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 abstract description 9
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 2
- 229960005069 calcium Drugs 0.000 description 83
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 38
- 241000700159 Rattus Species 0.000 description 38
- 230000037396 body weight Effects 0.000 description 32
- 235000010755 mineral Nutrition 0.000 description 23
- 229910000019 calcium carbonate Inorganic materials 0.000 description 19
- 229960003563 calcium carbonate Drugs 0.000 description 19
- 235000010216 calcium carbonate Nutrition 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 16
- 210000000689 upper leg Anatomy 0.000 description 13
- 230000004584 weight gain Effects 0.000 description 12
- 235000019786 weight gain Nutrition 0.000 description 12
- 208000001132 Osteoporosis Diseases 0.000 description 11
- 239000013641 positive control Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000008367 deionised water Substances 0.000 description 9
- 229910021641 deionized water Inorganic materials 0.000 description 9
- 210000003608 fece Anatomy 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 238000003304 gavage Methods 0.000 description 5
- 238000009629 microbiological culture Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229940069978 calcium supplement Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000010871 livestock manure Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940057948 magnesium stearate Drugs 0.000 description 2
- 239000011656 manganese carbonate Substances 0.000 description 2
- 235000006748 manganese carbonate Nutrition 0.000 description 2
- 229940093474 manganese carbonate Drugs 0.000 description 2
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 description 2
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000011655 sodium selenate Substances 0.000 description 2
- 235000018716 sodium selenate Nutrition 0.000 description 2
- 229960001881 sodium selenate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 108010011619 6-Phytase Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000500128 Cynomorium Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- RSYUFYQTACJFML-DZGCQCFKSA-N afzelechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C=C1 RSYUFYQTACJFML-DZGCQCFKSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- UNTBPXHCXVWYOI-UHFFFAOYSA-O azanium;oxido(dioxo)vanadium Chemical compound [NH4+].[O-][V](=O)=O UNTBPXHCXVWYOI-UHFFFAOYSA-O 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- LJAOOBNHPFKCDR-UHFFFAOYSA-K chromium(3+) trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Cl-].[Cr+3] LJAOOBNHPFKCDR-UHFFFAOYSA-K 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940116318 copper carbonate Drugs 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- -1 for example Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037345 metabolism of vitamins Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 229910000008 nickel(II) carbonate Inorganic materials 0.000 description 1
- ZULUUIKRFGGGTL-UHFFFAOYSA-L nickel(ii) carbonate Chemical compound [Ni+2].[O-]C([O-])=O ZULUUIKRFGGGTL-UHFFFAOYSA-L 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229940085127 phytase Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 235000019795 sodium metasilicate Nutrition 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention provides a composition of probiotics and glucosamine hydrochloride and application thereof in bone joint health, and relates to the technical field of probiotics. The composition of the probiotics and the glucosamine hydrochloride comprises the following components in parts by weight: 1-5 parts of lactobacillus plantarum LP-Onlly, 5161-5 parts of bifidobacterium lactis BI 5161-5 parts of bifidobacterium longum BL88-Onlly, 20-40 parts of glucosamine hydrochloride, 20-40 parts of milk mineral salt, 1-10 parts of oligosaccharide and 1-10 parts of casein phosphopeptide. The composition of the probiotics and the glucosamine hydrochloride has the functions of increasing bone density and promoting calcium absorption rate, and can be used for preparing corresponding food, medicines or health-care products.
Description
Technical Field
The invention belongs to the technical field of probiotics, and particularly relates to a composition of probiotics and glucosamine hydrochloride and application of the composition in bone and joint health.
Background
Osteoporosis (OP) is a systemic metabolic disease of bone characterized by low bone mass and microstructural destruction of bone tissue, leading to increased bone fragility and susceptibility to fracture, common in the elderly, but can occur at all ages. The Chinese white paper for preventing and treating osteoporosis indicates that at least 6944 million people in China have osteoporosis, 2.1 million people have low bone mass and have osteoporosis risk, 70-80% of middle-aged and old people fracture is caused by osteoporosis, wherein about 181 million people have new vertebral fracture every year, and 23 million cases of hip fracture occur. Researches show that the incidence rate of osteoporosis is 54-71% in 55-65 years old; the prevalence rate for elderly is 60.72% for men and 90.47% for women. With the advent of aging society, osteoporosis has become a high-incidence disease threatening the health of middle-aged and elderly people.
Bone density refers to the bone mineral content per unit volume and is an important marker of bone quality. The more mineral deposits, the greater the bone density and the firmer the bone. Bone density is the main standard for diagnosing osteoporosis, and the world health organization defines that osteoporosis is the condition that the bone density of an adult female is lower than the average value by 2.5 standard deviations.
For osteoporosis, calcium carbonate, calcium gluconate, calcium lactate and the like are common commercially available calcium supplements, which only provide mineral substances mainly including calcium, cannot solve the problems of calcium loss and bone mineralization promotion, and cannot determine whether the calcium supplements can be absorbed or not and how much the calcium supplements can be absorbed.
Disclosure of Invention
In view of the above, the present invention aims to provide a composition of probiotics and glucosamine hydrochloride and its application in bone and joint health, which can increase bone density, supplement calcium and promote calcium absorption, and is used for maintaining joint health.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a composition of probiotics and glucosamine hydrochloride, which comprises the following components in parts by weight: 1-5 parts of lactobacillus plantarum LP-Onlly, 5161-5 parts of bifidobacterium lactis BI 5161-5 parts of bifidobacterium longum BL88-Onlly, 20-40 parts of glucosamine hydrochloride, 20-40 parts of milk mineral salt, 1-10 parts of oligosaccharide and 1-10 parts of casein phosphopeptide.
Preferably, the oligosaccharides comprise: one or more of fructo-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide and galacto-oligosaccharide.
Preferably, the composition further comprises 2-9 parts by weight of auxiliary materials.
Preferably, the auxiliary materials include: maltodextrin, starch, lactose, anhydrous glucose, magnesium stearate and hypromellose.
The invention also provides application of the composition in preparing food for increasing bone density.
The invention also provides application of the composition in preparing a medicament for increasing bone density.
The invention also provides application of the composition in preparing health-care products for increasing bone density.
The invention also provides application of the composition in preparing food for promoting calcium absorption.
The invention also provides application of the composition in preparation of a medicine for promoting calcium absorption.
The invention also provides application of the composition in preparing health-care products for promoting calcium absorption.
The invention provides a composition of probiotics and glucosamine hydrochloride, which is prepared by compounding lactobacillus plantarum LP-Onlly, bifidobacterium lactis BI516, bifidobacterium longum BL 88-Only, glucosamine hydrochloride, milk mineral salt, oligosaccharide, casein phosphopeptide and auxiliary materials, and by probiotics with positive promotion effect on the absorption of mineral elements, the synthesis of vitamins and phytase is promoted, so that the phytic acid effect is inhibited, and the absorption of calcium is promoted while mineral substances are released; in addition, the probiotics can also produce short chain fatty acids, and the absorption of calcium is improved through the dissolving effect of the short chain fatty acids. In the composition, glucosamine hydrochloride is used for protecting cartilage and maintaining joint health, milk mineral salt is used for supplementing important nutrients for calcium and bone growth, probiotics is used for promoting calcium absorption, and casein phosphopeptide and other ingredients are supplemented after the three are compounded, so that the composition can be used for developing safe and effective food, medicine or health-care products with the functions of maintaining joint health, increasing bone density, supplementing calcium and promoting calcium absorption.
Deposit description
Lactobacillus plantarum (Lactobacillus plantarum), with the strain number LP-Onlly, was deposited in China general microbiological culture Collection center (CGMCC) at 06.12.2004 at the address of No. 3, Xilu-1, Beijing, the sunward, and the institute for microbiology, China academy of sciences, with the biological deposition number CGMCC No. 1258.
Bifidobacterium lactis (Bifidobacterium lactis) with strain number BI516, and is preserved in China general microbiological culture Collection Center (CCM) at 04 th 2016, specifically No. 3 of West Lu No.1 of Beijing Kogyo, and No.11959 of China academy of sciences (Microbiol research institute) in Cynomorium sunward.
Bifidobacterium longum (Bifidobacterium longum) with strain number BL88-Onlly, was deposited in China general microbiological culture Collection center at 13.07.2007 with the address of Beijing university Hokkaido No.1, West Lu No. 3, the south Kogyo area, Beijing, and the microbiological research institute of Chinese academy of sciences with the biological preservation number CGMCC No. 2107.
Detailed Description
The invention provides a composition of probiotics and glucosamine hydrochloride, which comprises the following components in parts by weight: 1-5 parts of lactobacillus plantarum LP-Onlly, 5161-5 parts of bifidobacterium lactis BI 5161-5 parts of bifidobacterium longum BL88-Onlly, 20-40 parts of glucosamine hydrochloride, 20-40 parts of milk mineral salt, 1-10 parts of oligosaccharide and 1-10 parts of casein phosphopeptide.
The composition comprises lactobacillus plantarum LP-Onlly, and the preferable weight part of the lactobacillus plantarum LP-Onlly in the composition is 3-5 parts. The Lactobacillus plantarum (Lactobacillus plantarum) LP-Onlly of the invention is preserved in China general microbiological culture Collection center (CGMCC) at 12.2004 and 06.12.h, with the address of No. 3 Xilu-Shih-1 of Beijing Korean district, and the number of biological preservation of the institute of microbiology of China academy of sciences is CGMCC No. 1258.
The composition comprises bifidobacterium lactis BI516, and the weight part of the bifidobacterium lactis BI516 in the composition is preferably 3-5 parts. The Bifidobacterium lactis BI516 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms at 2016, 01, 04, with the address of No. 3, West Lu No.1, North Chen, of the sunward area in Beijing, and the number of biological preservation is CGMCC No.11959, which is the institute of microbiology of the Chinese academy of sciences.
The composition comprises bifidobacterium longum BL88-Onlly, and the preferable weight part of the bifidobacterium longum BL88-Onlly in the composition is 3-5 parts. The Bifidobacterium longum (Bifidobacterium longum) BL88-Onlly is preserved in China general microbiological culture Collection center at 13 th month in 2007 with the address of No. 3 of No.1 of West Lu of Beijing Korean district, and the microbiological collection number of the China academy of sciences is CGMCC No. 2107.
In the invention, the lactobacillus plantarum LP-Onlly, the bifidobacterium lactis and the bifidobacterium longum BL88-Onlly can promote the synthesis of vitamin D through multiple mechanisms, improve the utilization rate of mineral substances, increase the level of blood calcium and increase the bone mineral density and the bone mineral content, and the strain has high activity and strong stability and can play an auxiliary role in promoting the absorption of calcium.
The composition comprises glucosamine hydrochloride, and the weight part of the glucosamine hydrochloride in the composition is preferably 25-35 parts. The glucosamine hydrochloride can reduce the symptoms of joint swelling, joint stiffness and the like caused by osteoarthritis or rheumatic arthritis, and greatly improve the life quality of arthritis patients. In the present invention, the source of the glucosamine hydrochloride is not particularly limited, and a conventional reagent in the art may be used.
The composition comprises milk mineral salt, and the weight part of the mineral salt in the composition is preferably 30-40 parts. The milk mineral salt of the present invention is preferably milk calcium. The milk mineral salt is a new resource food, is prepared by taking whey as a raw material and removing components such as protein, lactose and the like, contains 23-28% of calcium, contains phosphorus, magnesium, potassium, iron, zinc, copper and other trace elements with the same proportion as human bones, and has a protective effect on the bones. The source of the milk mineral salt is not particularly limited in the present invention, and conventional reagents in the art may be used.
The composition comprises oligosaccharide, and the weight part of the oligosaccharide in the composition is preferably 5-8 parts. The oligosaccharide of the present invention preferably comprises: one or more of fructo-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide and galacto-oligosaccharide. The oligosaccharide can be used as a proliferation factor of beneficial bacteria in intestinal tracts, and has an obvious effect on the proliferation of bifidobacteria; the Bifidobacterium has health promoting effect on human body, such as improving vitamin metabolism, wherein the metabolism of vitamin D, K is closely related to calcium metabolism.
The composition comprises casein phosphopeptide, and the weight part of the casein phosphopeptide in the composition is preferably 3-7 parts. The casein phosphopeptide takes cow milk casein as a raw material, and the bioactive peptide obtained by enzymatic hydrolysis, separation and purification has the capability of chelating calcium. Can be combined with divalent mineral ions such as calcium, iron, magnesium, zinc, selenium, etc. in small intestine environment to prevent phosphate precipitation, and enhance the concentration of soluble minerals in intestine, thereby promoting absorption and utilization. The casein phosphopeptide in the composition can combine and transport calcium in small intestine, is equivalent to a medium-short distance transportation protection tool of calcium, avoids the loss of calcium in the process of circulation, and promotes the absorption and utilization of calcium.
The composition comprises an auxiliary material, and the weight part of the auxiliary material in the composition is preferably 4.5-9 parts. The auxiliary materials of the invention preferably comprise: maltodextrin, starch, lactose, anhydrous glucose, magnesium stearate and hypromellose. The auxiliary materials can be used for adjusting the adhesiveness, the fluidity and the like of materials in the filling and tabletting processes of all components in the composition, for example, hydroxypropyl methylcellulose is a tablet premix coating material.
The invention also provides application of the composition in preparing food for increasing bone density. The food of the invention is preferably in the form of tablets, capsules or powders. The preparation method of the food is not particularly limited, and the conventional preparation method in the field can be used.
The invention also provides application of the composition in preparing a medicament for increasing bone density. The dosage form of the medicament of the invention is preferably tablets, capsules or powder. The preparation method of the medicine is not particularly limited, and the conventional preparation method in the field can be used.
The invention also provides application of the composition in preparing health-care products for increasing bone density. The dosage form of the health care product is preferably tablets, capsules or powder. The preparation method of the health care product is not particularly limited, and the conventional preparation method in the field can be utilized.
The invention also provides application of the composition in preparing food for promoting calcium absorption. The food of the invention is preferably in the form of tablets, capsules or powder. The preparation method of the food is not particularly limited, and the conventional preparation method in the field can be used.
The invention also provides application of the composition in preparation of a medicine for promoting calcium absorption. The dosage form of the medicament is preferably tablets, capsules or powder. The preparation method of the medicine is not particularly limited, and the conventional preparation method in the field can be used.
The invention also provides application of the composition in preparing health-care products for promoting calcium absorption. The dosage form of the health care product is preferably tablets, capsules or powder. The preparation method of the health care product is not particularly limited, and the conventional preparation method in the field can be utilized.
The composition of probiotic bacteria and glucosamine hydrochloride and the application thereof in bone joint health provided by the present invention will be described in detail with reference to the following examples, which should not be construed as limiting the scope of the present invention.
Example 1
The components are compounded into a composition according to the following weight percentage: lactobacillus plantarum LP-Onlly 2kg, bifidobacterium lactis BI 5165 kg, bifidobacterium longum BL88-Onlly 2kg, glucosamine hydrochloride 40kg, milk mineral salt 40kg, fructo-oligosaccharide 1kg, casein phosphopeptide 4kg, maltodextrin 5.5kg and magnesium stearate 0.5 kg.
The following experiment was carried out using the probiotic and glucosamine hydrochloride composition prepared in example 1 as a sample:
experiment 1: experiment for increasing bone Density
Samples and materials: using the composition of example 1 as a sample, the recommended amount for the human body of the composition is 3.78 g/day 60kg per day. The sample contained 11.3% calcium. 70 female adult rats (cleaning grade SD rats) 250-288 g are selected in the experiment. The temperature of the breeding room is 20-25 ℃, and the relative humidity is 40-70%.
Rats are anesthetized by intraperitoneal injection of 30 mg/kg-bw sodium pentobarbital solution, hairs at the positions of dorsal costal ridges are removed, iodine tincture and alcohol are respectively used for sterilization, bilateral ovaries are cut off, and another group of animals are taken for the same operation without cutting the bilateral ovaries and are used as a sham operation control group. 5 days after ovariectomy of the rats, vaginal smear examination was performed to eliminate the ovariectomized rats.
Dose design: according to the requirements of experimental items, three dosage groups of low, medium and high are set, namely 0.32, 0.63 and 1.89g/kg · bw, which are equivalent to 5 times, 10 times and 30 times of the recommended dosage of a human body. The rats after the operation are randomly divided into a model control group, a positive control group (1.0 mg/kg-bw estradiol), a calcium carbonate control group (the calcium level is the same as the high-dose calcium level) and a low, medium and high dose group according to the weight, wherein each group comprises 10 rats, and 10 sham-operated rats are taken as the sham-operated control group.
Preparing a test substance: samples 0.32, 0.63 and 1.89g are respectively taken, deionized water is added to 10mL, and test solutions of low, medium and high dosage groups are uniformly prepared; 534mg of calcium carbonate is taken, deionized water is added to 10mL, and the calcium carbonate is uniformly mixed to prepare a calcium carbonate control group test solution; deionized water was given to both the sham-operated group and the model control group. Each group of drinking water was deionized water.
Subject administration mode: the samples were administered by gavage with a gavage volume of 10mL/kg body weight. Gavage was performed once daily, each group of doses was designed to be given for 12 weeks, and the rats were given deionized water throughout the duration of the experiment, and body weights were recorded weekly, during which time the experimental rat feed formulations were as shown in table 1:
table 1 reference feed formulation
Note: 1. contains per kg of mixed mineral salts (g): potassium dihydrogen phosphate, 250.0; sodium chloride, 74.0; 46.6 parts of potassium sulfate; potassium citrate (mono-crystalline water), 28.0; magnesium oxide, 24.0; 6.06 parts of citric acid; zinc carbonate, 1.65; 0.63 parts of manganese carbonate; 0.30 parts of copper carbonate; potassium iodide, 0.01; sodium selenate, 0.01025; para-molybdate, 0.00795; sodium metasilicate (9 crystal waters), 1.45; chromium potassium sulfate (12 crystal waters), 0.275; boric acid, 0.0815; sodium fluoride, 0.0635; nickel carbonate, 0.318; lithium chloride 0.0174; ammonium vanadate, 0.0066; sucrose was added to 1 kg.
2. The vitamin composition contains (g) per kg of mixed vitamins: nicotinic acid, 3.0; calcium pantothenate, 1.6; pyridoxine hydrochloride, 0.7; thiamine hydrochloride, 0.60; vitamin B2, 0.60; folic acid, 0.2; biotin, 0.02; vitamin B12, 2.5; vitamin E, 15.0; 0.8 parts of vitamin A; vitamin D3, 0.25; vitamin K, 0.075; sucrose 974.655.
The results of measuring the effect of the composition described in example 1 on the body weight of rats are shown in table 2:
TABLE 2 Effect of samples on rat body weight
Note: indicates that the difference between each group in the same column and the comparison group of the model control group is significant, and P <0.05
As can be seen from Table 2, the average body weight and weight gain of the control group after four weeks are significantly higher than those of the control group after the false operation, which suggests that abnormal increase of body weight caused by hormone level disorder due to estrogen reduction of the animals after the operation may occur, indicating that the model is established. The average body weight in the middle and four weeks, the average body weight in the later four weeks and the weight gain of the positive control group are all obviously lower than those of the castration model control group. Compared with the model control group, the initial weight, the average weight per four weeks and the weight gain of each dose group have no obvious difference (P > 0.05). Compared with the calcium carbonate control group, the high-dose group has no significant difference in initial body weight, average body weight per four weeks and weight gain (P > 0.05).
Measuring the bone density of the femur: the rats were dissected, the left femur was dissected and baked to constant weight. The bone density of the midpoint of the femur and the distal end of the femur of a rat are measured by using a discovery-wi type bone densitometer, and the bone calcium content is measured by using an atomic absorption method, wherein the results are shown in table 3:
TABLE 3 Effect of samples on rat femoral weight, bone calcium and femoral bone Density
Note: indicates that the difference between each group in the same column and the model control group compared with each group is significant (P <0.05)
As can be seen from table 3, the indexes of the positive control group and the sham-operated control group, except for the dry weight of the femur, are significantly higher than those of the model control group. Compared with a model control group, the bone density and the bone calcium content of the distal end of the femur of the high-dose group and the calcium carbonate control group are obviously increased, and compared with the calcium carbonate control group with the same calcium level, the high-dose group has no significant difference (P is more than 0.05) in each index.
Under the experimental condition, the bone calcium content and the bone density value of the model control group are obviously lower than those of the sham operation group and the positive control group; the bone calcium content and the bone density value at the distal end of the femur of the high-dose group of the test object group are obviously higher than those of the model control group, and the composition can be considered to have the function of increasing the bone density of rats.
Experiment 2: calcium absorption test
Samples and materials: using the composition of example 1 as a sample, the recommended amount for the human body of the composition is 3.78 g/day 60kg per day. The sample contained 11.3% calcium. Weaning rats (cleaning grade SD rats) 60-79 g, 50 of 4 weeks after birth. The temperature of the breeding room is 20-25 ℃, and the relative humidity is 40-70%.
Dose design: the low, medium and high dose groups are set, namely 0.32, 0.63 and 1.89g/kg · bw, which are equivalent to 5 times, 10 times and 30 times of the recommended dose of a human body. A low calcium control and a calcium carbonate control (calcium level and high dose calcium level were the same) were established simultaneously.
Preparing a test substance: samples 0.32, 0.63 and 1.89g are respectively taken, deionized water is added to 10mL, and test solutions of low, medium and high dosage groups are uniformly prepared; 534mg of calcium carbonate is taken and added with deionized water to 10mL, and the calcium carbonate is evenly mixed to prepare a calcium carbonate control group test solution. Each group of drinking water was deionized water.
Subject administration mode: the samples were administered by gavage with a gavage volume of 10mL/kg body weight.
Calcium absorption experimental method
a, sample collection:
weaning rats born for 4 weeks were housed in cages. The rats were randomly divided into a low calcium control group, a calcium carbonate control group, and low, medium, and high dose groups according to body weight, each group consisting of 10 rats. Samples were gavaged to each group and the low calcium control group was given deionized water for 4 weeks. Body length and body weight were measured once a week. Calcium metabolism experiments were performed 3 days after experiment 3 weeks. Food intake was recorded for 3 days, feces were collected for 72 hours, and calcium content in the feces was measured. And drying the rat manure sample in an oven at the temperature of 80 ℃, cooling the rat manure sample in a dryer, and finely grinding the rat manure sample. Care was taken to prevent contamination during sample preparation. The feed formulation for the test rats during this period is shown in table 4:
TABLE 4 basic feed formulation (adjustment of Ca)2+Is 150mg/100g feed)
Note: 1. contains per kg of mixed mineral salts (g): potassium dihydrogen phosphate, 250.0; sodium chloride, 74.0; magnesium carbonate, 50.2; ferrous lactate, 5.4; zinc lactate, 4.16; 3.5 parts of manganese carbonate; 0.605 parts of copper sulfate pentahydrate; sodium selenate, 0.0066; potassium iodide, 0.00776; chromium trichloride hexahydrate, 0.292; sucrose was added to 1 kg.
2. The vitamin composition contains (g) per kg of mixed vitamins: vitamin a, 400,000 IU; vitamin D3, 100,000 IU; vitamin E, 500 IU; vitamin K, 5 mg; vitamin B1, 600 mg; vitamin B2, 600 mg; vitamin B6, 700 mg; vitamin B12, 1 mg; nicotinic acid, 3 g; folic acid, 200 mg; 1.6g of calcium pantothenate; biotin, 20 mg; sucrose was added to 1 kg.
b, measuring the bone calcium content: and (4) measuring by an atomic absorption method.
c apparent absorption rate of calcium:
calcium intake (mg) ═ feed calcium content (mg/g) × 3 days feed consumption + sample calcium intake
Calcium content (mg/g) in feces x 3 days feces excretion
Apparent absorption rate (%) of calcium (calcium intake-faecal calcium)/calcium intake × 100%
The results of the experiment are shown in table 5:
TABLE 5 Effect of samples on calcium absorption in the Experimental period of rats
Note: indicates that the difference between each group in the same column and the model control group compared with each group is significant (P <0.05)
As can be seen from Table 5, there was no apparent difference in body weight and body length between the dose groups compared with the low calcium control group (P > 0.05). The apparent absorption rate of calcium in the high dose group was significantly higher than that in the low calcium control group.
Example 2
The components are compounded into a composition according to the following weight ratio: 3kg of lactobacillus plantarum LP-Onlly, 3kg of bifidobacterium lactis BI 5165 kg, 5kg of bifidobacterium longum BL88-Onlly, 35kg of glucosamine hydrochloride, 40kg of milk mineral salt, 6kg of xylooligosaccharide, 4kg of casein phosphopeptide and 2kg of anhydrous glucose.
Using the composition obtained in example 2, the same bone density increasing experiment and calcium absorption experiment as in example 1 were performed, wherein the effect of the samples on the body weight of rats is shown in table 6:
TABLE 6 Effect of samples on rat body weight
Note: indicates that the difference between each group in the same column and the comparison group of the model control group is significant, and P <0.05
As can be seen from Table 6, the average body weight and weight gain of the control group in the middle and four weeks after the operation of the model are significantly higher than those of the control group in the false operation, which suggests that abnormal increase of body weight caused by hormone level disorder due to estrogen reduction of the animals after the operation is possible, and indicates that the model is established. The average body weight in the middle and four weeks, the average body weight in the later four weeks and the weight gain of the positive control group are all obviously lower than those of the castration model control group. Compared with the model control group, the initial weight, the average weight per four weeks and the weight gain of each dose group have no obvious difference (P > 0.05). Compared with the calcium carbonate control group, the high-dose group has no significant difference in initial body weight, average body weight per four weeks and weight gain (P > 0.05).
The results of the effect of the samples on rat femoral weight, bone calcium and femoral bone density are shown in table 7:
TABLE 7 Effect of samples on rat femoral weight, bone calcium and femoral bone Density
Note: indicates that the difference between each group in the same column and the model control group compared with each group is significant (P <0.05)
As can be seen from table 7, the indexes of the positive control group and the sham-operated control group, except for the dry weight of the femur, are significantly higher than those of the model control group. Compared with a model control group, the bone density and the bone calcium content of the distal end of the femur of the high-dose group and the calcium carbonate control group are obviously increased, and compared with the calcium carbonate control group with the same calcium level, the high-dose group has no significant difference (P is more than 0.05) in each index.
Under the experimental condition, the bone calcium content and the bone density value of the model control group are obviously lower than those of the sham operation group and the positive control group; the bone calcium content and the bone density value at the distal end of the femur of the high-dose group of the test object group are obviously higher than those of the model control group, and the composition can be considered to have the function of increasing the bone density of rats.
The results of the calcium absorption experiments are shown in table 8:
TABLE 8 Effect of samples on calcium absorption in the Experimental period of rats
Note: indicates that the difference between each group in the same column and the model control group compared with each group is significant (P <0.05)
As can be seen from Table 8, there was no apparent difference in body weight and body length between the dose groups compared with the low calcium control group (P > 0.05). The apparent absorption rate of calcium in the medium-dose and high-dose groups is obviously higher than that in the low-calcium control group.
Example 3
The components are compounded into a composition according to the following weight ratio: 4kg of lactobacillus plantarum LP-Onlly, 4kg of bifidobacterium lactis BI 5163 kg, 2kg of bifidobacterium longum BL88-Onlly, 25kg of glucosamine hydrochloride, 40kg of milk mineral salt, 7kg of xylooligosaccharide, 10kg of casein phosphopeptide, 5kg of anhydrous glucose and 4kg of maltodextrin.
Using the composition obtained in example 3, the same bone density increasing experiment and calcium absorption experiment as in example 1 were conducted, wherein the effect of the samples on the body weight of rats is shown in Table 9:
TABLE 9 Effect of samples on rat body weight
Note: indicates that the difference between each group in the same column and the comparison group of the model control group is significant, and P <0.05
As can be seen from Table 9, the average body weight and weight gain of the control group in the middle and four weeks after the operation of the model are significantly higher than those of the control group in the false operation, which suggests that abnormal increase of body weight caused by hormone level disorder due to estrogen reduction of the animals after the operation may occur, indicating that the model is established. The average body weight in the middle and four weeks, the average body weight in the later four weeks and the weight gain of the positive control group are all obviously lower than those of the castration model control group. Compared with the model control group, the initial weight, the average weight per four weeks and the weight gain of each dose group have no obvious difference (P > 0.05). Compared with the calcium carbonate control group, the high-dose group has no significant difference in initial body weight, average body weight per four weeks and weight gain (P > 0.05).
The results of the effect of the samples on rat femoral weight, bone calcium and femoral bone density are shown in table 10:
TABLE 10 Effect of samples on rat femoral weight, bone calcium and femoral bone Density
Note: indicates that the difference between each group in the same column and the model control group compared with each group is significant (P <0.05)
As can be seen from table 10, the indexes of the positive control group and the sham-operated control group, except for the dry weight of the femur, are significantly higher than those of the model control group. Compared with a model control group, the bone density and the bone calcium content of the distal end of the femur of the high-dose group and the calcium carbonate control group are obviously increased, and compared with the calcium carbonate control group with the same calcium level, the high-dose group has no significant difference (P is more than 0.05) in each index.
Under the experimental condition, the bone calcium content and the bone density value of the model control group are obviously lower than those of the sham operation group and the positive control group; the bone calcium content and the bone density value at the distal end of the femur of the high-dose group of the test object group are obviously higher than those of the model control group, and the composition can be considered to have the function of increasing the bone density of rats.
The results of the calcium absorption experiments are shown in table 11:
TABLE 11 Effect of samples on calcium absorption in the Experimental period of rats
Note: indicates that the difference between each group in the same column and the model control group compared with each group is significant (P <0.05)
As can be seen from Table 11, there was no apparent difference in body weight and body length between the dose groups compared with the low calcium control group (P > 0.05). The apparent absorption rate of calcium in the high dose group was significantly higher than that in the low calcium control group.
In conclusion, the invention provides a composition of probiotics and glucosamine hydrochloride, which has the functions of increasing bone density and promoting calcium absorption rate and can be used for preparing corresponding food, medicines or health-care products in bone joint health.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (7)
1. The composition of probiotics and glucosamine hydrochloride is characterized by comprising the following components in parts by weight: 2 parts of lactobacillus plantarum LP-Onlly, 2 parts of bifidobacterium lactis BI 5165 parts, 2 parts of bifidobacterium longum BL88-Onlly, 40 parts of glucosamine hydrochloride, 40 parts of milk mineral salt, 1 part of fructo-oligosaccharide, 4 parts of casein phosphopeptide and 6 parts of auxiliary materials;
the auxiliary materials comprise: maltodextrin and magnesium stearate, wherein the weight part ratio of the maltodextrin to the magnesium stearate is 5.5: 0.5.
2. Use of the composition of claim 1 for the preparation of a food product for increasing bone density.
3. Use of a composition according to claim 1 for the manufacture of a medicament for increasing bone density.
4. Use of the composition of claim 1 for the preparation of a health product for increasing bone density.
5. Use of the composition of claim 1 for the preparation of a food product for promoting calcium absorption.
6. Use of a composition according to claim 1 for the manufacture of a medicament for promoting calcium absorption.
7. Use of the composition of claim 1 for the preparation of a health product for promoting calcium absorption.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811594602.9A CN109432388B (en) | 2018-12-25 | 2018-12-25 | Composition of probiotics and glucosamine hydrochloride and application of composition in bone joint health |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811594602.9A CN109432388B (en) | 2018-12-25 | 2018-12-25 | Composition of probiotics and glucosamine hydrochloride and application of composition in bone joint health |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109432388A CN109432388A (en) | 2019-03-08 |
| CN109432388B true CN109432388B (en) | 2021-12-31 |
Family
ID=65535638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811594602.9A Active CN109432388B (en) | 2018-12-25 | 2018-12-25 | Composition of probiotics and glucosamine hydrochloride and application of composition in bone joint health |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109432388B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116195742B (en) * | 2021-11-30 | 2024-07-09 | 内蒙古伊利实业集团股份有限公司 | Application of bifidobacterium lactis BL-99 in cartilage protection |
| CN114196603B (en) * | 2022-01-25 | 2024-05-24 | 山东向日葵生物工程有限公司 | Bifidobacterium lactis SF-B21 and application thereof in preparation of bone mineral density increasing fermented beverage |
| CN114634901B (en) * | 2022-05-18 | 2022-08-30 | 微康益生菌(苏州)股份有限公司 | Lactobacillus casei LC16 for promoting bone health and culture method and application thereof |
| CN115948296B (en) * | 2022-12-23 | 2024-02-27 | 四川高福记生物科技有限公司 | Lactobacillus plantarum for improving musculoskeletal health and/or improving exercise capacity, and composition and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423035A (en) * | 2011-11-25 | 2012-04-25 | 苏州先阔生物科技有限公司 | Health care food containing xylo-oligosaccharides for assisting in treating quinquagenarian retrogressive bone joint diseases |
| CN103446577A (en) * | 2013-09-03 | 2013-12-18 | 庞会心 | Medicine composition for preventing and treating arthritis and application thereof |
| CN105166938A (en) * | 2015-08-11 | 2015-12-23 | 湖南科尔生物技术有限公司 | Casein and bone protocalcium compound probiotic preparation |
| CN106107980A (en) * | 2016-06-28 | 2016-11-16 | 张标 | A kind of can put on weight, height, calcium content of bone and the osteoarthrosis health product of raising bone density |
| CN106174045A (en) * | 2016-07-25 | 2016-12-07 | 三株福尔制药有限公司 | A kind of probiotics fermention calcium-supplementing preparation and preparation method thereof |
| CN106421757A (en) * | 2016-09-09 | 2017-02-22 | 杨森健 | Composition for assisting in treating gout and increasing bone density and application of composition |
| CN106880040A (en) * | 2017-04-11 | 2017-06-23 | 姜红成 | Prepare the fermentation composition and preparation method with the plant enzyme suitable for the conditioning maintenance of rheumatism osteoarthritis patients |
-
2018
- 2018-12-25 CN CN201811594602.9A patent/CN109432388B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102423035A (en) * | 2011-11-25 | 2012-04-25 | 苏州先阔生物科技有限公司 | Health care food containing xylo-oligosaccharides for assisting in treating quinquagenarian retrogressive bone joint diseases |
| CN103446577A (en) * | 2013-09-03 | 2013-12-18 | 庞会心 | Medicine composition for preventing and treating arthritis and application thereof |
| CN105166938A (en) * | 2015-08-11 | 2015-12-23 | 湖南科尔生物技术有限公司 | Casein and bone protocalcium compound probiotic preparation |
| CN106107980A (en) * | 2016-06-28 | 2016-11-16 | 张标 | A kind of can put on weight, height, calcium content of bone and the osteoarthrosis health product of raising bone density |
| CN106174045A (en) * | 2016-07-25 | 2016-12-07 | 三株福尔制药有限公司 | A kind of probiotics fermention calcium-supplementing preparation and preparation method thereof |
| CN106421757A (en) * | 2016-09-09 | 2017-02-22 | 杨森健 | Composition for assisting in treating gout and increasing bone density and application of composition |
| CN106880040A (en) * | 2017-04-11 | 2017-06-23 | 姜红成 | Prepare the fermentation composition and preparation method with the plant enzyme suitable for the conditioning maintenance of rheumatism osteoarthritis patients |
Non-Patent Citations (3)
| Title |
|---|
| 氨基葡萄糖对绝经后骨质疏松模型大鼠的保护作用;李哲等;《中国海洋药物》;20170831;第36卷(第4期);第29-34页 * |
| 益生菌制剂对钙缺乏骨质疏松症的防治作用;张颜廷等;《中国骨质疏松杂志》;20160131;第22卷(第1期);第45-48页 * |
| 肠道菌群与骨骼代谢;李路娇等;《中华骨质疏松和骨矿盐疾病杂志》;20180530;第11卷(第3期);第317-322页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109432388A (en) | 2019-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109432388B (en) | Composition of probiotics and glucosamine hydrochloride and application of composition in bone joint health | |
| CN102318835A (en) | Composition for reducing bone loss and preparation method thereof | |
| CN110393728B (en) | Lactobacillus, pharmaceutical composition thereof and use of edible composition in treating, preventing or improving bone diseases | |
| CN103458876A (en) | Galenic composition suitable for administration to a non-human animal, uses thereof, and associated methods | |
| CN108576816A (en) | A kind of composition increasing bone density | |
| TWI719691B (en) | Use of lactobacillus reuteri gkr1 for preparing composition of reducing uric acid | |
| CN104605226A (en) | Healthcare product with function of increasing bone mineral density | |
| Huo et al. | Preparation and biological efficacy of haddock bone calcium tablets | |
| CN104146260A (en) | Health-care food for improving bone density and preparation method thereof | |
| CN116875515B (en) | Lactobacillus paracasei GF027 for improving memory and children growth and application thereof | |
| TW201410254A (en) | Novel protein material | |
| CN103211972B (en) | A kind of kidney-tonifying composition and preparation method thereof | |
| WO2008098503A1 (en) | Culture medium for bifidobacterium longum, composition comprising the same and preparation method thereof | |
| CN108420890B (en) | Composition with blood fat reducing effect and preparation method thereof | |
| CN103239480B (en) | Calcium supplement for animals and chewable tablets of calcium supplement | |
| CN103238711A (en) | Food healthcare tea granules for promoting lead excreting | |
| CN104305228A (en) | Food for enhancing immunity and preparation method thereof | |
| CN109601880B (en) | Health food for increasing bone mineral density | |
| CN107029162A (en) | Pharmaceutical composition, preparation method and the preparation of enhancing development | |
| KR20170096758A (en) | the GamiSibjeondaebo composite with the funtion of the treatment of scull fracture | |
| CN103349278A (en) | Vitamin mineral tablets | |
| CN111298099A (en) | Iron-supplementing composition and preparation method and application thereof | |
| CN108095114A (en) | A kind of Chinese medicine and health food for increasing bone density and preparation method thereof | |
| RU2760674C1 (en) | Use of preparations of polyscias filicifolia plant or its fragments for treatment of elementoses and their consequences | |
| TWI574696B (en) | Novel protein material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |